Neuropathic pain, such as postherpetic neuralgia, is a disabling condition that affects 1-2% of patients in the general population. The underlying mechanisms is currently unclear. Consequently, physicians are limited in their ability to manage neuropathic pain. The purpose of this study was to determine the role of gut microbiota in the development of neuropathic pain, by modulating infiltration of immunity-related cells and neural pathways after neuronal injury.
Professor Matthew Chan, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
The project was awarded $A70,000 through the ANZCA research grants program for 2022.
A gut bacterium that was depleted in patients with chronic pain was identified. This bacterium also enhanced pain signal transmission through the vagus nerve to the brain to suppress the brain region that is involved in pain perception.
Overall, the experiments established a microbiota-based model for assessing chronic pain and identified a potential pain-alleviating probiotic. A further clinical trial to test this probiotic in preventing and managing chronic pain is warrant.
A manuscript has been submitted to a peer-review journal for consideration. US provisional patent has been obtained - The Novel probiotics and their analgesic effect on chronic neuropathic pain. (63/568,487)
Last modified: